Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
about
Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Cost-effectiveness analysis of ...... ey disease patients in France.
@en
Cost-effectiveness analysis of ...... ey disease patients in France.
@nl
type
label
Cost-effectiveness analysis of ...... ey disease patients in France.
@en
Cost-effectiveness analysis of ...... ey disease patients in France.
@nl
prefLabel
Cost-effectiveness analysis of ...... ey disease patients in France.
@en
Cost-effectiveness analysis of ...... ey disease patients in France.
@nl
P2093
P2860
P1433
P1476
Cost-effectiveness analysis of ...... ey disease patients in France.
@en
P2093
Armand Abergel
Aurore Clément
Chizoba Nwankwo
Eric Thervet
Isabelle Durand-Zaleski
Laurie Levy-Bachelot
Vincent Di Martino
P2860
P304
P356
10.1371/JOURNAL.PONE.0194329
P407
P577
2018-03-15T00:00:00Z